Linked Life Data

1355007

Source:http://linkedlifedata.com/resource/pubmed/id/1355007

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
17
pubmed:dateCreated
1992-9-29
pubmed:abstractText
Cutaneous recurrences of breast carcinomas were treated with 10 i.l. injections of nIFNs alpha and gamma delivered in combination (7 lesions) or singly (11 with nIFN-alpha, one with nIFN-gamma). Histologically confirmed complete regressions occurred in 5 of 7 lesions treated with nIFN-alpha/nIFN-gamma and in 5 of 11 recurrences injected with nIFN-alpha alone. In all cases specimens were obtained before and after therapy. In addition, in some cases (4 treated with nIFN-alpha/nIFN-gamma, 2 with nIFN-alpha, one with nIFN-gamma) multiple recurrences were injected simultaneously and were excised 24 h after 1, 3, and 10 injections and 21 days after completion of therapy. The main findings observed in the treated lesions undergoing complete and partial regressions included: (a) inhibition of mitotic activity and up-regulation of antigenic expression (mammary epithelial membrane antigen, intercellular adhesion molecule 1, HLA-DR) by the carcinoma cells; (b) activation of macrophages and dendrocytes with marked expression of HLA-DR and HLA-A,B,C; (c) infiltration of the dermis and tumors by activated T-lymphocytes (CD3+, CD4+, CD8+); (d) questionable participation by B-lymphocytes and natural killer cells; (e) activation of endothelium with enhancement of antigenic expression (intercellular adhesion molecule 1, HLA-DR), procoagulant activity, and vascular permeability. The responses elicited by nIFN-alpha/nIFN-gamma were greater than those caused by either IFN used alone. It appears that in these patients the IFNs exerted an antiproliferative action and potentiated a cell-mediated immunological response liminally present in the neoplastic tissues prior to therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0008-5472
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4571-81
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:1355007-Administration, Cutaneous, pubmed-meshheading:1355007-Blood Vessels, pubmed-meshheading:1355007-Breast Neoplasms, pubmed-meshheading:1355007-Carcinoma, pubmed-meshheading:1355007-Cell Adhesion Molecules, pubmed-meshheading:1355007-HLA Antigens, pubmed-meshheading:1355007-Humans, pubmed-meshheading:1355007-Immunohistochemistry, pubmed-meshheading:1355007-Intercellular Adhesion Molecule-1, pubmed-meshheading:1355007-Interferon-alpha, pubmed-meshheading:1355007-Interferon-gamma, pubmed-meshheading:1355007-Langerhans Cells, pubmed-meshheading:1355007-Lymphocytes, pubmed-meshheading:1355007-Macrophages, pubmed-meshheading:1355007-Membrane Glycoproteins, pubmed-meshheading:1355007-Mucin-1, pubmed-meshheading:1355007-Receptors, Interleukin-2, pubmed-meshheading:1355007-Recurrence, pubmed-meshheading:1355007-Skin Neoplasms
pubmed:year
1992
pubmed:articleTitle
Cellular events accompanying regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma.
pubmed:affiliation
Arthur Purdy Stout Laboratory of Surgical Pathology, Columbia University, New York, New York 10032.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't